---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-025929"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2022-09-15T23:59:59+00:00"
generated_at: "2026-06-23T09:21:09.881214+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio cuts workforce by 20% and identifies over $1.5M in annual cost savings to focus on LB1148

## Summary
- Reduction in force of 20% with estimated cash severance of $380,148.
- Anticipates annual cost savings of ~$773,000 from workforce reduction plus up to $800,000 from other cuts, totaling >$1.5M.
- Company to focus all resources on advancing lead asset LB1148, with Phase 3 enrollment targeted within 18-24 months.
- Payment of severance expected to be substantially completed by end of Q1 2023.

## SEC filing metadata
- accession: 0001493152-22-025929
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2022-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000149315222025929/0001493152-22-025929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000149315222025929/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-025929
- JSON: https://secwatch.observer/filing/0001493152-22-025929.json
- Plain text: https://secwatch.observer/filing/0001493152-22-025929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.